Home › Funds › PSP Research LLC › NAMS

PSP Research LLC position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

PSP Research LLC reported holding 12,000 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$407K, representing 0.22% of its reported portfolio and ranking #33 among its reported holdings. PSP Research LLC has disclosed NAMS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)12.00K sh
Reported value held$406.68K
Portfolio Weight0.22%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's NAMS position evolved

PSP Research LLC first disclosed a stake in NAMS in Q4 2025 at 14,920 shares (US$523K). Across 3 filings, PSP Research LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 12,000 shares valued at US$407K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 14.92K $523.39K New
Q1 2026 15.00K $480.15K Add
Q2 2026 12.00K $406.68K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →